Therefore, the high levels of miR-19a in the serum of patients with HER2+ breast cancer who received anti-HER2 therapy and had good prognosis may result from an effective Th1-mediated immune response that enhanced NK-mediated tumor cell lysis in ADCC. This evidence concerns the gene ERBB2 and breast cancer.